Roth Capital Sets Expectations On CTI BioPharma Ahead Of PERSIST-1 Phase 3 Results
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Cell Therapeutics (NASDAQ:CTIC) with a $4.50 price target, which implies an upside of 91% from current levels.
Chattopadhyay noted, “PERSIST-1 is expected to report during 1Q15. While the study is still blinded, conversation with management suggests that the patients enrolled in the phase 3 closely approximated real world MF (based on baseline platelet count). Importantly, despite enrolling patients across the entire disease spectrum, dropout rates from the study has been very low suggesting a manageable safety profile and pointing to intriguing hints of efficacy, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 4.5% and a 48.6% success rate. Chattopadhyay has a -14.3% average return when recommending CTIC, and is ranked #961 out of 3412 analysts.